108 related articles for article (PubMed ID: 32020225)
1. Variant analysis of prostate cancer in Japanese patients and a new attempt to predict related biological pathways.
Kasajima R; Yamaguchi R; Shimizu E; Tamada Y; Niida A; Tremmel G; Kishida T; Aoki I; Imoto S; Miyano S; Uemura H; Miyagi Y
Oncol Rep; 2020 Mar; 43(3):943-952. PubMed ID: 32020225
[TBL] [Abstract][Full Text] [Related]
2. Identification of key genes and pathways in castrate-resistant prostate cancer by integrated bioinformatics analysis.
Wu YP; Ke ZB; Lin F; Wen YA; Chen S; Li XD; Chen SH; Sun XL; Huang JB; Zheng QS; Xue XY; Wei Y; Xu N
Pathol Res Pract; 2020 Oct; 216(10):153109. PubMed ID: 32853947
[TBL] [Abstract][Full Text] [Related]
3. Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer.
Ye Y; Li SL; Wang SY
PLoS One; 2018; 13(8):e0198055. PubMed ID: 30138363
[TBL] [Abstract][Full Text] [Related]
4. Impact of RNA‑binding motif 3 expression on the whole transcriptome of prostate cancer cells: An RNA sequencing study.
Dong Q; Lv C; Zhang G; Yu Z; Kong C; Fu C; Zeng Y
Oncol Rep; 2018 Oct; 40(4):2307-2315. PubMed ID: 30106430
[TBL] [Abstract][Full Text] [Related]
5. The Identification of Key Gene Expression Signature in Prostate Cancer.
Huang Y; Cao Q; Song Z; Ruan H; Wang K; Chen K; Zhang X
Crit Rev Eukaryot Gene Expr; 2020; 30(2):153-168. PubMed ID: 32558494
[TBL] [Abstract][Full Text] [Related]
6. Five lncRNAs Associated With Prostate Cancer Prognosis Identified by Coexpression Network Analysis.
Gong X; Ning B
Technol Cancer Res Treat; 2020; 19():1533033820963578. PubMed ID: 33084528
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome analysis of differentially expressed genes and pathways associated with mitoxantrone treatment prostate cancer.
Li S; Li R; Ma Y; Zhang C; Huang T; Zhu S
J Cell Mol Med; 2019 Mar; 23(3):1987-2000. PubMed ID: 30592148
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
Pashaei E; Pashaei E; Ahmady M; Ozen M; Aydin N
PLoS One; 2017; 12(6):e0179543. PubMed ID: 28651018
[TBL] [Abstract][Full Text] [Related]
9. Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model.
Lin Y; Chen F; Shen L; Tang X; Du C; Sun Z; Ding H; Chen J; Shen B
J Transl Med; 2018 May; 16(1):134. PubMed ID: 29784056
[TBL] [Abstract][Full Text] [Related]
10. Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach.
Fang E; Zhang X; Wang Q; Wang D
Cancer Biomark; 2017 Dec; 20(4):553-561. PubMed ID: 28800317
[TBL] [Abstract][Full Text] [Related]
11. Identification of Potential Key Genes and Pathways in Enzalutamide-Resistant Prostate Cancer Cell Lines: A Bioinformatics Analysis with Data from the Gene Expression Omnibus (GEO) Database.
Zheng L; Dou X; Ma X; Qu W; Tang X
Biomed Res Int; 2020; 2020():8341097. PubMed ID: 32724813
[TBL] [Abstract][Full Text] [Related]
12. Metabolic deregulation in prostate cancer.
Srihari S; Kwong R; Tran K; Simpson R; Tattam P; Smith E
Mol Omics; 2018 Oct; 14(5):320-329. PubMed ID: 30215656
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer small non-coding RNA transcriptome in Arabs.
Shan J; Al-Rumaihi K; Chouchane K; Al-Bozom I; Rabah D; Farhat K; Chouchane L
J Transl Med; 2017 Dec; 15(1):260. PubMed ID: 29268752
[TBL] [Abstract][Full Text] [Related]
14. Network-based analysis of prostate cancer cell lines reveals novel marker gene candidates associated with radioresistance and patient relapse.
Seifert M; Peitzsch C; Gorodetska I; Börner C; Klink B; Dubrovska A
PLoS Comput Biol; 2019 Nov; 15(11):e1007460. PubMed ID: 31682594
[TBL] [Abstract][Full Text] [Related]
15. Construction and analysis of protein-protein interaction networks based on proteomics data of prostate cancer.
Chen C; Shen H; Zhang LG; Liu J; Cao XG; Yao AL; Kang SS; Gao WX; Han H; Cao FH; Li ZG
Int J Mol Med; 2016 Jun; 37(6):1576-86. PubMed ID: 27121963
[TBL] [Abstract][Full Text] [Related]
16. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
[TBL] [Abstract][Full Text] [Related]
17. Identification of candidate miRNA biomarkers from miRNA regulatory network with application to prostate cancer.
Zhang W; Zang J; Jing X; Sun Z; Yan W; Yang D; Shen B; Guo F
J Transl Med; 2014 Mar; 12():66. PubMed ID: 24618011
[TBL] [Abstract][Full Text] [Related]
18. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.
Berglund AE; Rounbehler RJ; Gerke T; Awasthi S; Cheng CH; Takhar M; Davicioni E; Alshalalfa M; Erho N; Klein EA; Freedland SJ; Ross AE; Schaeffer EM; Trock BJ; Den RB; Cleveland JL; Park JY; Dhillon J; Yamoah K
Prostate Cancer Prostatic Dis; 2019 May; 22(2):292-302. PubMed ID: 30367117
[TBL] [Abstract][Full Text] [Related]
19. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
Khani F; Wobker SE; Hicks JL; Robinson BD; Barbieri CE; De Marzo AM; Epstein JI; Pritchard CC; Lotan TL
J Pathol; 2019 Sep; 249(1):79-89. PubMed ID: 30993692
[TBL] [Abstract][Full Text] [Related]
20. In silico identification of key genes and signaling pathways targeted by a panel of signature microRNAs in prostate cancer.
Baruah MM; Sharma N
Med Oncol; 2019 Apr; 36(5):43. PubMed ID: 30937635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
